Career Paths in Proteomics

Graphic: Leza BerardoneThis is the beginning," pronounced J. Craig Venter, president of Celera Genomics in Rockville, Md., at a press conference at the American Association for the Advancement of Science annual meeting in February. "There [are] 30,000 genes, and up to one-quarter of a million proteins [encoded by them] in 100 trillion different combinations--that's how many cells we have. That's why we don't think this is the blueprint for humanity; it's the starting point of understanding how t

Written byKaren Young Kreeger
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

"The peak of demand for those skilled in this field is yet to come," says Enrique Dalmasso, manager of Fremont, Calif.-based Ciphergen Biosystems' biomarker discovery center, because companies and research labs are just starting to ramp up, as are many pharmaceutical firms that are developing their own internal proteomics groups. Three types of companies lay claim to being involved in proteomics: tools and instrumentation firms, contract service companies, and information database firms. Instrumentation firms like BioRad Laboratories of Hercules, Calif., supply two-dimensional gel electrophoresis, Applied Biosystems of Foster City, Calif., provides mass spectrometers, and Ciphergen offers protein arrays. These tools variously separate and classify proteins by their electrical charge, weight, and binding affinities. The contract service companies such as Large Scale Biology of Vacaville, Calif., and Genomic Solutions of Ann Arbor, Mich., offer services for separating and identifying proteins. And then there are the information database firms such as Celera ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies